FDA Approves Treatment for for Chronic Immune Thrombocytopenia

Article

Officials with the FDA have approved fostamatinib disodium hexahydrate (Tavalisse, Rigel) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment

Officials with the FDA have approved fostamatinib disodium hexahydrate (Tavalisse, Rigel) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

The only other approved therapies for ITP are steroids, blood platelet productions boosters, and splenectomy, but there remained a significant need for additional options, as many patients achieve benefit from them.

"Chronic ITP is challenging to treat because the heterogeneity of the disease makes it difficult to predict how an individual patient will respond to available treatments and not all patients can find a treatment that works well for them," James Bussel, MD, the professor emeritus of pediatrics at Weill Cornell Medicine, said in statement

. "The FDA approval of fostamatinib arms physicians with a new treatment option, which works via a novel mechanism."

Bussel, who served as a consultant and paid member of the advisory board for Rigel Pharmaceuticals, Inc, was also the principal study investigator on the FIT Phase 3 program, consisting of 2 phase 3 clinical trials which the FDA utilized to make its decision.

Click to continue reading on MD Magazine.

Related Videos
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
Physician and kidneys
Image credit: gamjai - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.